PBL’s Post

Let us help you to optimize your AAV production efficacy with advanced aggregation analysis using TEM. #AAV #TEM #aggregation #QuTEM

Optimize Production Efficacy with Advanced Aggregation Analysis Using TEM  At QuTEM (formerly Vironova BioAnalytics), we provide cutting-edge analytical tools for monitoring particle clusters and aggregates in your samples over time. By leveraging Transmission Electron Microscopy (TEM), we offer precise quantification of individual particles and aggregates, expressed either by total particle count or as a percentage ratio of the sample. This detailed analysis is vital for enhancing the stability and efficacy of virus-based vaccines and gene therapy products. Our expertise in nanoparticle TEM (nsTEM) enables us to visually and quantitatively assess aggregation—a key factor in product performance. Our team employs proprietary software for semi-automated detection and classification of viral particles and aggregates in TEM images. This approach delivers robust, quantitative insights into particle aggregation, supporting the optimization of your biopharmaceutical production processes. Contact us today and learn more about aggregation analysis! #AAV #TEM #QuTEM #aggregation #technology

TBD: Mark your calendars to join our talk with Charles Hill Sr. Field Application Scientist Upstream as he discusses the innovations that improved production and cost of monoclonal antibodies manufacturing and how these innovations are influencing the production of emerging advanced therapeutics such as cell and gene therapies. Key takeaway- By analyzing the successes and challenges of mAb production we explore technology developments including: -Upstream process intensification -High-capacity high mass transfer chromatography -Consistent scalability of TFF -Robust analytics Mark your calendars! https://lnkd.in/gJy63PX6 #BPIConf #Bioprocessing #Processintensification #Upstream #Downstream #Analytics #fluidmanagemet #monoclonalantibody #genetherapy #celltherapy #repligen #xcellaft #krosflotfdf #krosflokrm #avitide #flowvpx #solovpe

Unlocking Optimal Conditions for HEK293T Cell Expansion Using SCINUS Bioreactor Technology The need for scalable and reproducible methodologies in cell culture processes has increased with the advancement of biopharmaceutical research. HEK293T cell line is versatile and widely used in gene therapy applications such as viral production for the generation of CAR-T treatment. To meet the growing demand for point-of-care manufacturing of this therapy, efficient scale-up of these cells is crucial. A common strategy for this is the use of microcarriers, such as Cytodex 1, which is a popular choice for HEK293T culture. Using design-of-experiments (DoE) methodology, we investigated the influence of rocking speed, seeding density, and time of initial pause on HEK293T growth in the SCINUS Cell Expansion System (SCES), to understand factor interactions and their influence on cell proliferation. https://lnkd.in/d2WMcwjz #aspenalert #biotech #bioprocess

Our "Methodology for Identifying Current and Future Skills Gaps: Future-Proofing the Bioprocessing Sector As It Embraces Industry 4.0 Principles" is featured in this month's BioProcess International - link that that and other invaluable insights from the industry below. #Biopharma #Biomanufacturing #genetherapy #celltherapy #antibodytherapeutics #vaccines #pharmaceutical #Biologics

The January-February 2024 Production Issue of BioProcess International is available in print and digital! This issue features fascinating articles from talented professionals. Read on for a preview of the articles linked below: Getting Cell Therapy Right at the Source by Becky Cap. Top Trends in Global Biomanufacturing: 20 Years of Analyzing Biologics Production and Supply by Erica L. Friedman. Comparability for Cell and Gene Therapy Products: A Challenge and an Opportunity by K.R. Poudel, Zenobia Taraporewala, Diane Blumenthal, Deep Shah and Kathleen Francissen. Lessons in Bioreactor Scale-Up: Part 1 — Exploring Introductory Principles by Muhammad Arshad Chaudhry. A Methodology for Identifying Current and Future Skills Gaps: Future-Proofing the Bioprocessing Sector As It Embraces Industry 4.0 Principles, Part 1 by Jason Beckwith, Paul Rooney, Gregor Adams, Stephen Goldrick, William Nixon and Stavros Kourtzidis. Characterizing Oxygen Mass Transfer and Shear During Cell Culture: Calculating the Maximum Cell Density Supported By a 20,000-Liter Stirred-Tank Bioreactor by Naveenganesh Muralidharan, Emma Bolduc and Mark Davis. Streamline Manufacturing of Antibody-Based Therapeutics with Novel Purification Approaches by Laurens Sierkstra. A Scalable, Two-Step Purification Process for Plasmid DNA by Simon Åberg. Introducing a Multitiered Classification System for Downstream Process Intensification by Martin Lobedann, PhD. Expansion into Late Drug Discovery and Early Development by Derrick Katayama. Can Alarms Be Batch-Release Parameters? A European Perspective by GERARDO VECE and Gaurav Walia. #cellandgenetherapy #biomanufacturing #downstreamprocessing Follow the link below to read the full issue: https://lnkd.in/gDYbAAzG

📢 AGC Biologics, a global contract developer, offers a standardized approach to manufacturing AAVs and LVVs for gene therapy. 🔬 The approach covers the entire vector manufacturing process, from transfection to purification, using adherent or suspension processes. 💡 AGC Bio is working to overcome challenges such as removing the final sterilization step and improving the polishing step of AAV manufacturing. 🌐 This standardized approach allows AGC Bio to be flexible and cater to clients' needs in different phases of clinical trials. #BioprocessUpdates #viralvector #manufacturing #genetherapy #AAV #LVV #transfection #purification #adherentprocess #suspensionprocess #sterilization #polishingstep #clinicaltrials #AGCBio #standardizedapproach #flexibility ▷ Read the full article here: 📎 https://lnkd.in/dnHb_Vdz

Our "Methodology for Identifying Current and Future Skills Gaps: Future-Proofing the Bioprocessing Sector As It Embraces Industry 4.0 Principles" is featured in this month's BioProcess International - link and other invaluable insights from the industry below. https://lnkd.in/eJ-MDvNc #Biopharma #Biomanufacturing #genetherapy #celltherapy #antibodytherapeutics #vaccines #pharmaceutical #Biologics

We're excited to share that PackGene is launching three new products and services to empower your gene editing and research projects! To celebrate, we're offering a special 30% discount until 📅May 30, 2024. ◾ Off-the-Shelf mRNA Products: Speed up your research with our ready-to-ship mRNA including fluorescent proteins, reporters and more. Ensure that your projects advance without delay. ◾ LNP Formulation Sample Kit: Tailor your research with our LNP sampler kits, including EGFP or Firefly Luciferase mRNA, as well as empty LNP for control. Perfect for fine-tuning applications in cell lines or animal models, with rapid shipping. ◾ Fast mRNA Service for Gene Editing: Expedite your gene editing with mRNA services for Cas9, Cas9 Nickase, Cre recombinase, and more, delivered swiftly in as little as a few days to 2 weeks. Leverage these powerful tools to propel your research forward. Take advantage of our limited-time offer and unlock the potential of your projects with PackGene's precision and efficiency. 🔗 Place your order today and transform your research trajectory! https://lnkd.in/gjUqBhPm #PackGene #GeneEditing #mRNA #LipidNanoParticle #LNP #ResearchInnovation #ScienceSale

🔬 Shaping the Future: Viral Vector & Plasmid DNA Manufacturing 🚀 Get PDF Sample Copy: https://lnkd.in/dUpFzMvi The Viral Vector & Plasmid DNA Manufacturing market is at the core of groundbreaking advancements in gene therapy and vaccine development. As the demand for innovative therapies grows, so does the need for scalable and efficient manufacturing solutions. 🧬 With cutting-edge technologies, automation, and quality assurance, industry leaders are pushing the boundaries of what's possible in biotech. From personalized medicine to advanced vaccines, the future is bright for this market! 💡 The global viral vector manufacturing market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $12.8 billion by 2028, growing at a CAGR of 18.2% from 2023 to 2028. Key players in the viral vector and plasmid DNA manufacturing market include Lonza  (Switzerland), Merck KGaA, Darmstadt, Germany, Thermo Fisher Scientific (US), Charles River Laboratories (US), and many more... #Biotech #GeneTherapy #ViralVectors #PlasmidDNA #HealthcareInnovation #Biomanufacturing #FutureOfHealthcare